Research ArticleOncology
Comparison of the RGD Motif–Containing αvβ6 Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC
Saskia Roesch, Thomas Lindner, Max Sauter, Anastasia Loktev, Paul Flechsig, Martin Müller, Walter Mier, Rolf Warta, Gerhard Dyckhoff, Christel Herold-Mende, Uwe Haberkorn and Annette Altmann
Journal of Nuclear Medicine November 2018, 59 (11) 1679-1685; DOI: https://doi.org/10.2967/jnumed.118.210013
Saskia Roesch
1Department of Otorhinolaryngology, University Hospital Heidelberg, Heidelberg, Germany
2Division of Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
Thomas Lindner
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Max Sauter
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
4Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany
Anastasia Loktev
5Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany; and
Paul Flechsig
6Department of Radiology, University Hospital Heidelberg, Heidelberg, Germany
Martin Müller
5Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany; and
Walter Mier
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Rolf Warta
1Department of Otorhinolaryngology, University Hospital Heidelberg, Heidelberg, Germany
2Division of Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
Gerhard Dyckhoff
1Department of Otorhinolaryngology, University Hospital Heidelberg, Heidelberg, Germany
Christel Herold-Mende
1Department of Otorhinolaryngology, University Hospital Heidelberg, Heidelberg, Germany
2Division of Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
Uwe Haberkorn
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
5Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany; and
Annette Altmann
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
5Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 11
November 1, 2018
Comparison of the RGD Motif–Containing αvβ6 Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC
Saskia Roesch, Thomas Lindner, Max Sauter, Anastasia Loktev, Paul Flechsig, Martin Müller, Walter Mier, Rolf Warta, Gerhard Dyckhoff, Christel Herold-Mende, Uwe Haberkorn, Annette Altmann
Journal of Nuclear Medicine Nov 2018, 59 (11) 1679-1685; DOI: 10.2967/jnumed.118.210013
Comparison of the RGD Motif–Containing αvβ6 Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC
Saskia Roesch, Thomas Lindner, Max Sauter, Anastasia Loktev, Paul Flechsig, Martin Müller, Walter Mier, Rolf Warta, Gerhard Dyckhoff, Christel Herold-Mende, Uwe Haberkorn, Annette Altmann
Journal of Nuclear Medicine Nov 2018, 59 (11) 1679-1685; DOI: 10.2967/jnumed.118.210013
Jump to section
Related Articles
Cited By...
- Clinical Translation of a 68Ga-Labeled Integrin {alpha}v{beta}6-Targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer
- A Conversation Between Uwe Haberkorn and Johannes Czernin
- Preclinical Development and First-in-Human Imaging of the Integrin {alpha}v{beta}6 with [18F]{alpha}v{beta}6-Binding Peptide in Metastatic Carcinoma
- Using backbone-cyclized Cys-rich polypeptides as molecular scaffolds to target protein-protein interactions